Association of On-Treatment Neutrophil-to-Eosinophil Ratio With Treatment Responses in Patients With mRCC Treated With Nivolumab/Ipilimumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma
Cancers (Basel) 2022 Aug 07;14(15)3830, YW Chen, MD Tucker, LC Brown, HA Yasin, KK Ancell, AJ Armstrong, KE Beckermann, NB Davis, MR Harrison, EG Kaiser, RK McAlister, KR Schaffer, DE Wallace, DJ George, WK Rathmell, BI Rini, T ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.